Company news
Thalia Therapeutics PLC news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Final Results
April 23, 2024
Oral Delivery Update
April 18, 2024
in-vitro siRNA update
February 15, 2024
Patent Grant
January 19, 2024
AAV Viral Vector Update
January 8, 2024
Nuvec® R&D and Strategy Update
December 7, 2023
N4 Pharma Launches New Interactive Investor Hub
November 30, 2023
Investor Presentation via Investor Meet Company
October 9, 2023
Investor Presentation
October 2, 2023
Acquisition of Controlling Interest in Nanogenics
September 28, 2023
Patent Grant and Board Change
July 25, 2023
Grant Award for Professor Chengzhong Yu
June 27, 2023
siRNA update
April 25, 2023
Second Price Monitoring Extn
February 14, 2023
Price Monitoring Extension
January 17, 2023
Result of Broker Offer and Total Voting Rights
November 22, 2022
Broker Offer to raise a maximum of £1 million
November 18, 2022
Patent filing update
November 1, 2022
Double siRNA Testing Update
October 4, 2022
Operational Update
September 14, 2022
Work Programme Update
July 15, 2022
Notice of AGM & Posting Annual Report and Accounts
February 24, 2022
Granting of Patents
January 31, 2022
Oncology work programme update
January 25, 2022
EPO Patent Granted
October 1, 2021
Operations Update
September 14, 2021
Notification of Intention to Grant Patent
February 11, 2021
Placing to raise £2 million
December 9, 2020
Formulation Work Update
December 3, 2020
SP Angel Research Note
November 18, 2020
Launch of Nuvec® Oncology Treatment Programme
November 9, 2020
Covid-19 Proof of Concept Update
September 14, 2020
Exercise of Options
September 8, 2020
Technology Transfer and Manufacturing Contract
September 1, 2020
Exercise of Warrants and Issue of Equity
August 26, 2020
Positive Covid-19 In Vitro Study Results
August 12, 2020
Change of Adviser
July 15, 2020
Work Programme and Strategic Update
July 6, 2020
Result of General Meeting and grant of warrants
June 18, 2020
Posting of circular and notice of general meeting
June 1, 2020
Covid-19 Project Update
May 28, 2020
N4 Pharma: Grant of Options
May 18, 2020
Placing to raise £2m & appointment of Joint Broker
May 13, 2020
New Nuvec® opportunity and patent filing
April 24, 2020
Attendance at the Company's annual general meeting
April 17, 2020
Changes to AGM
March 25, 2020
Posting of Annual Report and Notice of AGM
March 4, 2020
Research Collaboration Agreement
February 11, 2020
Update on Nuvec® process improvements
January 29, 2020
Results of University of Queensland Study
August 20, 2019
Calls
- Thalia Therapeutics (LSE:THAT) — Interim results for the six months ended 30 June 2026
Sep 30, 2026
Transcript - Thalia Therapeutics (LSE:THAT) — Investor Presentation
Jun 24, 2026
Transcript - Thalia Therapeutics (LSE:THAT) — Interim results for the six months ended 30 June 2025
Sep 25, 2025
Transcript - Thalia Therapeutics (LSE:THAT) — Investor Webinar
Feb 4, 2025
Transcript
Decks
- Investor Presentation (October 2023)
Investor deck · 18 slides · Oct 2, 2023